The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells
The Journal of Immunology · 2024
DOI: 10.4049/jimmunol.2300212 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Trini A Ochoa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Hauptthemen laut MEDLINE: Proteasome Inhibitors, Antineoplastic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health.
Abstract (Originalsprache)
The proteasome inhibitor bortezomib (BTZ) is proposed to deplete activated B cells and plasma cells. However, a complete picture of the mechanisms underlying BTZ-induced apoptosis in B lineage cells remains to be established. In this study, using a direct in vitro approach, we show that deletion of the tumor suppressor and cell cycle regulator p53 rescues recently activated mouse B cells from BTZ-induced apoptosis. Furthermore, BTZ treatment elevated intracellular p53 levels, and p53 deletion constrained apoptosis, as recently stimulated cells first transitioned from the G1 to S phase of the cell cycle. Moreover, combined inhibition of the p53-associated cell cycle regulators and E3 ligases MDM2 and anaphase-promoting complex/cyclosome induced cell death in postdivision B cells. Our results reveal that efficient cell cycle progression of activated B cells requires proteasome-driven inhibition of p53. Consequently, BTZ-mediated interference of proteostasis unleashes a p53-dependent cell cycle–associated death mechanism in recently activated B cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
- Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
- Division of Transplant Surgery, University of Cincinnati College of Medicine, Cincinnati, OH.
ORCID-Profile: Trini A Ochoa, Amy Rossi, E Steve Woodle, David Hildeman
Förderung
- NIAID NIH HHS
- HHS | National Institutes of Health
Zitieren
APA
Ochoa, T. A., Rossi, A., Woodle, E. S., Hildeman, D., & Allman, D. (2024). The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300212
Vancouver
Ochoa TA, Rossi A, Woodle ES, Hildeman D, Allman D. The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300212
BibTeX
@article{Ochoa2024,
author = {Ochoa, Trini A and Rossi, Amy and Woodle, E Steve and Hildeman, David and Allman, David},
title = {The Proteasome Inhibitor Bortezomib Induces p53-Dependent Apoptosis in Activated B Cells},
journal = {The Journal of Immunology},
year = {2024},
doi = {10.4049/jimmunol.2300212}
}
EUVIMED